ProCE Banner Activity

Recent Advances in CAR T-Cell Therapy for Hematologic Malignancies

Clinical Thought
CAR T-cell therapies continue to generate excitement for clinicians and patients with hematologic malignancies. In this commentary, I outline key recent advances and key upcoming clinical research to be presented at ASH 2020.

Released: December 01, 2020

Expiration: November 30, 2021

Share

Faculty

Michael Wang

Michael Wang, MD

Associate Professor
Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Michael Wang, MD

Associate Professor
Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael Wang MD, has disclosed that he has received consulting fees from AstraZeneca/Acerta, BeiGene, Celgene, Guidepoint Global, InnoCare, Janssen, Juno, Kite, Loxo, Oncternal, Omi, Pharmacyclics, Pulse, Targeted Oncology, and VelosBio and funds for research support from AstraZeneca/Acerta, BeiGene, BioInvent, InnoCare, Janssen, Juno, Kite, Lilly, Loxo, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, and Verastem.